About: Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCOV RT-PCR assay for the qualitative detection of SARS-CoV-2 from upper respiratory tract specimens

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCOV RT-PCR assay for the qualitative detection of SARS-CoV-2 from upper respiratory tract specimens Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCOV RT-PCR assay for the qualitative detection of SARS-CoV-2 from upper respiratory tract specimens
Creator	Li, Haiying Hayden, Mary Moore, Nicholas Lindsley, Jennifer Schejbal, Debra
source	MedRxiv
abstract	We compared the ability of 2 commercial molecular amplification assays [RealTime SARS-CoV-2 on the m2000 (Abbott) and ID NOW COVID-19 (Abbott)] and a laboratory developed test [modified CDC 2019-nCoV RT-PCR assay with RNA extraction by eMag(R) (bioMeriux) and amplification on QuantStudio 6 or ABI 7500 Real-Time PCR System (Life Technologies)] to detect SARS-CoV-2 RNA in upper respiratory tract specimens. Discrepant results were adjudicated by medical record review. 200 nasopharyngeal swab specimens in viral transport medium were collected from symptomatic patients between March 27 and April 9, 2020. Results were concordant for 167 specimens (84.3% overall agreement), including 94 positive and 73 negative specimens. The RealTime SARS-CoV-2 assay on the m2000 yielded 33 additional positive results, 25 of which were also positive by the modified CDC assay but not by the ID NOW COVID-19 assay. In a follow-up evaluation, 97 patients for whom a dry nasal swab specimen yielded negative results by the ID NOW COVID-19 assay had a paired nasopharyngeal swab specimen collected in viral transport medium and tested by the RealTime SARS-CoV-2 assay; SARS-CoV-2 RNA was detected in 13 (13.4%) of these specimens. Medical record review deemed all discrepant results to be true positives. The ID NOW COVID-19 test was fastest (as soon as 5 minute for positive and 13 minute for negative result.) The RealTime SARS-CoV-2 assay on the m2000 detected more cases of COVID-19 infection than the modified CDC assay or the ID NOW COVID-19 test.
has issue date	2020-05-06(xsd:dateTime)
bibo:doi	10.1101/2020.05.02.20088740
has license	medrxiv
sha1sum (hex)	67653b786a8e50593b43635728646a94bdce61e4
schema:url	https://doi.org/10.1101/2020.05.02.20088740
resource representing a document's title	Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCOV RT-PCR assay for the qualitative detection of SARS-CoV-2 from upper respiratory tract specimens
resource representing a document's body	covid:67653b786a8e50593b43635728646a94bdce61e4#body_text
is schema:about of	named entity 'assay' named entity 'additional' named entity 'specimens' named entity 'positive' named entity 'patients' named entity 'true positives' named entity '167' named entity 'UPPER RESPIRATORY TRACT' named entity 'SYMPTOMATIC' named entity 'REAL-TIME PCR ' named entity 'March 22' named entity 'ABI' named entity 'negative' named entity 'positive' named entity 'SARS-CoV-2' named entity 'assay' named entity 'swab' named entity 'collected' named entity 'COVID-19' named entity 'RealTime' named entity 'test' named entity 'evaluation' named entity 'modified' named entity 'molecular' named entity 'SARS-CoV-2' named entity 'nasopharyngeal swab' named entity 'SARS-CoV-2' named entity 'VTM' named entity 'Real-Time PCR' named entity 'medical record' named entity 'SARS-CoV-2' named entity 'FDA' named entity 'nucleic acids' named entity 'SARS-CoV-2' named entity 'EUA' named entity 'CDC' named entity 'confounding' named entity 'U.S.' named entity 'RNA' named entity 'United States' named entity 'RNA' named entity 'point of care' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'cough' named entity 'epidemiology' named entity 'true positive' named entity 'Wuhan' named entity 'preprint' named entity 'CDC' named entity 'medRxiv' named entity 'standard reference method' named entity 'RealTime' named entity 'IVD' named entity 'preprint' named entity 'EUA' named entity 'RealTime' named entity 'SARS-CoV-2' named entity 'infection' named entity 'CDC' named entity 'RealTime' named entity 'nucleic acid' named entity 'CDC' named entity 'SARS-CoV-2' named entity 'RNA sequences' named entity 'SARS-CoV-2' named entity 'reverse transcriptase polymerase chain reaction' named entity 'nasopharyngeal swab' named entity 'preprint' named entity 'preprint' named entity 'RealTime' named entity 'RNA' named entity 'SARS-CoV-2' named entity 'CDC' named entity 'NIH' named entity 'SARS-CoV-2' named entity 'Centers for Disease Control and Prevention' named entity 'Lenexa' named entity 'gene' named entity 'SARS-CoV-2' named entity 'RNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software